X

Trial Profile

AIRE - Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer - a Prospectively Randomized Phase IV Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Vinorelbine (Primary) ; Capecitabine; Paclitaxel
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Pharmacodynamics
Acronyms AIRE

Most Recent Events

12 Sep 2023 Planned number of patients changed from 82 to 84.
14 Apr 2023 Planned End Date changed from 15 Mar 2023 to 15 Sep 2023.
14 Apr 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com